<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article79</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/FOURIER" style="display:block; margin-bottom:10px;">FOURIER Original</a></li>
<h2><strong>FOURIER</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Evolocumab in Patients with Cardiovascular Disease".The New England Journal of Medicine. 2017. 376:1713-1722.PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1Clinical Question<br/>
2Bottom Line<br/>
3Major Points<br/>
4Guidelines<br/>
5Design<br/>
6Population<br/>
6.1Inclusion Criteria<br/>
6.2Exclusion Criteria<br/>
6.3Baseline Characteristics<br/>
7Interventions<br/>
8Outcomes<br/>
8.1Primary Outcome<br/>
8.2Secondary Outcomes<br/>
9Criticisms<br/>
10Funding<br/>
11Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with established cardiovascular disease and elevated LDL cholesterol levels despite statin therapy, does evolocumab further reduce cardiovascular events?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Among patients with cardiovascular disease and elevated LDL cholesterol levels on statin therapy, the addition of evolocumab further reduced LDL cholesterol and cardiovascular events.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
While statins have significantly reduced cardiovascular events through LDL cholesterol lowering, not all patients reach target LDL cholesterol levels with statins alone. Evolocumab, a monoclonal antibody inhibiting PCSK9, has been shown to lower LDL cholesterol by approximately 60%. Its cardiovascular event reduction potential was unclear.<br/>
<br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of 2017, no guidelines reflecting the outcomes of this trial have been published.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, double-blind, parallel-group, randomized, placebo-controlled trial<br/>
N=27,564 patients with established cardiovascular disease and LDL cholesterol ≥70 mg/dL<br/>
Evolocumab at either 140 mg every 2 weeks or 420 mg monthly (n=13,784)<br/>
Placebo (n=13,780)<br/>
Median follow-up: 2.2 years<br/>
Primary efficacy outcome: Composite of cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
Age 40-85 years<br/>
Clinical evidence of atherosclerotic cardiovascular disease (MI, nonhemorrhagic stroke, symptomatic peripheral artery disease)<br/>
LDL cholesterol ≥70 mg/dL or non-HDL cholesterol ≥100 mg/dL on statin therapy<br/>
Exclusion Criteria<br/>
Not specified<br/>
Baseline Characteristics<br/>
Mean age: 63 years<br/>
Female: 24.6%<br/>
History of MI: 81.1%<br/>
Previous stroke: 19.4%<br/>
Symptomatic peripheral artery disease: 13.2%<br/>
Use of high-intensity statin therapy: 69.3%<br/>
Use of ezetimibe: 5.2%<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Randomization to receive subcutaneous injections of evolocumab or matching placebo<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
Primary composite endpoint: 9.8% in evolocumab vs. 11.3% in placebo (HR 0.85; 95% CI, 0.79 to 0.92; P&lt;0.001)<br/>
Secondary Outcomes<br/>
Key secondary composite endpoint (cardiovascular death, MI or stroke): 5.9% in evolocumab vs. 7.4% in placebo (HR 0.80; 95% CI, 0.73 to 0.88; P&lt;0.001)<br/>
Other individual outcomes: Significant reductions for MI, stroke, and coronary revascularization<br/>
No significant effect on cardiovascular mortality, hospitalization for unstable angina, overall death, or urgent revascularization<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Relatively short follow-up duration compared to other lipid-lowering trials<br/>
The majority but not all patients on high-intensity statin therapy; low ezetimibe use<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by Amgen, the manufacturer of evolocumab.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Additional references cited within the full text of the article and further data available in the supplementary material published alongside the article.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
